We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock
LUMO

Delisted

LUMO was delisted on the 11th of December, 2024.

Back to rankings

126 hedge funds and large institutions have $199M invested in Lumos Pharma, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 32 increasing their positions, 41 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

211% more call options, than puts

Call options by funds: $15.2M | Put options by funds: $4.89M

131% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 13

68% more capital invested

Capital invested by funds: $118M → $199M (+$80.7M)

15% more funds holding

Funds holding: 110 → 126 (+16)

22% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 41

Holders
126
Holders Change
+16
Holders Change %
+14.55%
% of All Funds
3.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
32
Reduced
41
Closed
13
Calls
$15.2M
Puts
$4.89M
Net Calls
+$10.3M
Net Calls Change
+$8.11M

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$10.6M
2
Millennium Management
Millennium Management
New York
+$9.07M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$5.89M
4
BBA
Baker Bros. Advisors
New York
+$4.32M
5
PA
Perceptive Advisors
New York
+$3.83M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$8.65M
2
GPP
Great Point Partners
Connecticut
-$8.03M
3
BIM
Bogle Investment Management
Massachusetts
-$3.26M
4
Deutsche Bank
Deutsche Bank
Germany
-$1.71M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCP
26
GSA Capital Partners
United Kingdom
$1.34M +$977K +12,736 +654%
AIM
27
Alambic Investment Management
California
$1.07M +$898K +11,708 New
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.06M -$3.45K -45 -0.4%
BCM
29
Bridgeway Capital Management
Texas
$1.02M +$852K +11,111 New
RPAM
30
Rhenman & Partners Asset Management
Sweden
$1.02M +$852K +11,111 New
American Century Companies
31
American Century Companies
Missouri
$963K +$806K +10,509 New
Deutsche Bank
32
Deutsche Bank
Germany
$932K -$1.71M -22,238 -69%
HCM
33
Highbridge Capital Management
New York
$872K +$730K +9,517 New
SIM
34
Spark Investment Management
New York
$869K +$728K +9,489 New
Barclays
35
Barclays
United Kingdom
$843K +$387K +5,046 +121%
Charles Schwab
36
Charles Schwab
California
$838K +$37.4K +488 +6%
Dimensional Fund Advisors
37
Dimensional Fund Advisors
Texas
$795K -$364K -4,742 -35%
TA
38
Teachers Advisors
New York
$755K +$295K +3,844 +87%
RSCM
39
Rock Springs Capital Management
Maryland
$738K – – –
Simplex Trading
40
Simplex Trading
Illinois
$674K +$565K +7,366 New
Bank of Montreal
41
Bank of Montreal
Ontario, Canada
$672K +$341K +4,442 +154%
AllianceBernstein
42
AllianceBernstein
Tennessee
$624K – – –
TAM
43
Tiverton Asset Management
Delaware
$577K -$61.3K -799 -11%
NWM
44
Northwest Wealth Management
Iowa
$553K -$31.9K -416 -6%
Jacobs Levy Equity Management
45
Jacobs Levy Equity Management
New Jersey
$551K +$199K +2,597 +76%
PPA
46
Parametric Portfolio Associates
Washington
$551K +$223K +2,904 +93%
CS
47
Credit Suisse
Switzerland
$548K -$3.22K -42 -0.7%
Allianz Asset Management
48
Allianz Asset Management
Germany
$528K -$997 -13 -0.2%
MCM
49
Moore Capital Management
New York
$509K +$426K +5,556 New
Goldman Sachs
50
Goldman Sachs
New York
$498K +$3.3K +43 +0.8%
1
2
3 4 5

LUMO Hedge Fund Activity: Q3 2017 in Review

126 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q3 2017, worth a combined $199M — up 68% from $118M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new LUMO positions and 13 closed out — a net gain of 17 holders — while 32 added to existing stakes and 41 trimmed.

The largest buyer was Redmile Group, opening a new position worth an estimated $10.6M. The largest seller was OrbiMed, cutting an estimated $8.65M.

  • 126 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q3 2017, up from 110 in Q2 2017.
  • Funds reported $199M of Lumos Pharma, Inc. Common Stock stock for Q3 2017, up 68% quarter-over-quarter.
  • 30 funds opened new Lumos Pharma, Inc. Common Stock positions in Q3 2017 and 13 closed out, a net change of +17 holders.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q3 2017 was Redmile Group, an estimated $10.6M added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q3 2017 was OrbiMed, an estimated $8.65M sold.

Based on aggregated 13F filings for Q3 2017.